Y-mAbs Therapeutics (YMAB) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

YMAB Stock Forecast


Y-mAbs Therapeutics stock forecast is as follows: an average price target of $20.50 (represents a 37.86% upside from YMAB’s last price of $14.87) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

YMAB Price Target


The average price target for Y-mAbs Therapeutics (YMAB) is $20.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $13.00. This represents a potential 37.86% upside from YMAB's last price of $14.87.

YMAB Analyst Ratings


Buy

According to 6 Wall Street analysts, Y-mAbs Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for YMAB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Y-mAbs Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 28, 2024Nicole GerminoTruist Financial$21.00$12.3370.32%41.22%
May 10, 2024Robert BurnsH.C. Wainwright$22.00$12.8770.94%47.95%
Apr 05, 2024Etzer DaroutBMO Capital$26.00$14.5678.57%74.85%
May 10, 2023YMAB)to OutperformWedbush$13.00$9.8931.38%-12.58%
Row per page
Go to

The latest Y-mAbs Therapeutics stock forecast, released on Jun 28, 2024 by Nicole Germino from Truist Financial, set a price target of $21.00, which represents a 70.32% increase from the stock price at the time of the forecast ($12.33), and a 41.22% increase from YMAB last price ($14.87).

Y-mAbs Therapeutics Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$23.00
Last Closing Price$14.87$14.87$14.87
Upside/Downside-100.00%-100.00%54.67%

In the current month, the average price target of Y-mAbs Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Y-mAbs Therapeutics's last price of $14.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2024Cantor FitzgeraldUnderperformUnderperformHold
Sep 09, 2024Morgan StanleyBuyBuyHold
Aug 16, 2024Cantor Fitzgerald-OverweightInitialise
Aug 13, 2024Morgan StanleyBuyBuyHold
Aug 13, 2024BMO CapitalUnderperformUnderperformHold
May 10, 2024H.C. WainwrightBuyBuyHold
Apr 05, 2024BMO CapitalOutperformOutperformHold
May 10, 2023Wedbush-OutperformUpgrade
Jan 05, 2023Cowen & Co.-Market PerformDowngrade
Oct 31, 2022GuggenheimBuyBuyHold
Row per page
Go to

Y-mAbs Therapeutics's last stock rating was published by Cantor Fitzgerald on Sep 09, 2024. The company gave YMAB a "Underperform" rating, the same as its previous rate.

Y-mAbs Therapeutics Financial Forecast


Y-mAbs Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue--------$23.36M$20.45M$20.75M$20.25M$31.45M$12.54M$10.80M$10.49M$9.60M$8.96M$10.95M$5.38M$20.75M
Avg Forecast$27.95M$27.50M$26.67M$25.29M$25.19M$23.28M$23.02M$22.21M$20.95M$20.97M$20.33M$15.58M$20.35M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
High Forecast$27.95M$27.50M$26.67M$25.29M$25.19M$25.19M$23.02M$22.21M$22.15M$20.97M$20.33M$15.58M$20.35M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
Low Forecast$27.95M$27.50M$26.67M$25.29M$25.19M$21.90M$23.02M$22.21M$19.60M$20.97M$20.33M$15.58M$20.35M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
# Analysts333345424222111122222
Surprise %--------1.12%0.98%1.02%1.30%1.55%1.04%0.96%0.96%0.89%0.82%1.49%0.13%1.79%

Y-mAbs Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $22.21M, with a low forecast of $22.21M, and a high forecast of $22.21M. YMAB's average Quarter revenue forecast represents a -4.95% decrease compared to the company's last Quarter revenue of $23.36M (Dec 23).

Y-mAbs Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts333345424222111122222
EBITDA--------$-74.00K$-7.75M$-7.22M$-7.50M$-1.15M$-25.79M$-39.76M$-27.50M$-35.47M$-28.56M$-22.50M$33.88M$-19.82M
Avg Forecast$-12.53M$-12.33M$-11.95M$-11.33M$-11.29M$-10.43M$-10.32M$-37.05M$-9.39M$-9.40M$-9.11M$-33.68M$-30.65M$-5.39M$-5.03M$-30.62M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
High Forecast$-12.53M$-12.33M$-11.95M$-11.33M$-11.29M$-9.82M$-10.32M$-29.64M$-8.78M$-9.40M$-9.11M$-26.95M$-24.52M$-5.39M$-5.03M$-24.50M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
Low Forecast$-12.53M$-12.33M$-11.95M$-11.33M$-11.29M$-11.29M$-10.32M$-44.46M$-9.93M$-9.40M$-9.11M$-40.42M$-36.78M$-5.39M$-5.03M$-36.75M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
Surprise %--------0.01%0.82%0.79%0.22%0.04%4.79%7.90%0.90%7.34%5.86%6.85%-1.81%3.81%

2 analysts predict YMAB's average Quarter EBITDA for Jun 21 to be $-3.28M, with a high of $-3.28M and a low of $-3.28M. This is -109.69% lower than Y-mAbs Therapeutics's previous annual EBITDA (Mar 21) of $33.88M.

Y-mAbs Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts333345424222111122222
Net Income--------$-2.28M$-7.75M$-6.30M$-5.10M$-401.00K$-29.04M$-42.32M$-28.44M$-38.03M$-28.86M$-22.94M$33.41M$-19.93M
Avg Forecast$-6.65M$-6.39M$-7.17M$-6.33M$-5.65M$-6.95M$-5.47M$-37.31M$-8.63M$-8.27M$-10.65M$-33.92M$-31.89M$-31.26M$-29.30M$-30.84M$-30.48M$-25.71M$-29.20M$58.56M$-20.59M
High Forecast$-6.65M$-6.39M$-7.17M$-6.33M$-5.65M$-4.47M$-5.47M$-29.85M$-7.27M$-8.27M$-10.65M$-27.14M$-25.51M$-31.26M$-29.30M$-24.67M$-30.48M$-25.71M$-29.20M$70.27M$-20.59M
Low Forecast$-6.65M$-6.39M$-7.17M$-6.33M$-5.65M$-7.94M$-5.47M$-44.77M$-9.08M$-8.27M$-10.65M$-40.70M$-38.26M$-31.26M$-29.30M$-37.00M$-30.48M$-25.71M$-29.20M$46.85M$-20.59M
Surprise %--------0.26%0.94%0.59%0.15%0.01%0.93%1.44%0.92%1.25%1.12%0.79%0.57%0.97%

Y-mAbs Therapeutics's average Quarter net income forecast for Jun 21 is $-29.20M, with a range of $-29.20M to $-29.20M. YMAB's average Quarter net income forecast represents a -187.40% decrease compared to the company's last Quarter net income of $33.41M (Mar 21).

Y-mAbs Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts333345424222111122222
SG&A--------$11.13M$10.20M$11.27M$12.25M$10.79M$13.63M$23.08M$13.44M$15.14M$13.99M$13.47M$11.97M$14.63M
Avg Forecast$34.50M$33.95M$32.92M$31.21M$31.09M$28.73M$28.41M$17.86M$25.86M$25.89M$25.09M$19.23M$13.08M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$20.98M$14.31M
High Forecast$34.50M$33.95M$32.92M$31.21M$31.09M$31.09M$28.41M$21.44M$27.34M$25.89M$25.09M$19.23M$15.70M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$25.17M$14.31M
Low Forecast$34.50M$33.95M$32.92M$31.21M$31.09M$27.03M$28.41M$14.29M$24.19M$25.89M$25.09M$19.23M$10.47M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$16.78M$14.31M
Surprise %--------0.43%0.39%0.45%0.64%0.82%0.92%1.67%1.00%1.14%1.04%1.49%0.57%1.02%

Y-mAbs Therapeutics's average Quarter SG&A projection for Mar 24 is $17.86M, based on 2 Wall Street analysts, with a range of $14.29M to $21.44M. The forecast indicates a 60.42% rise compared to YMAB last annual SG&A of $11.13M (Dec 23).

Y-mAbs Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts333345424222111122222
EPS--------$-0.00$-0.00$-0.14$-0.12$-0.01$-0.66$-0.97$-0.65$-0.87$-0.66$-0.53$0.80$-0.48
Avg Forecast$-0.15$-0.15$-0.16$-0.14$-0.13$-0.16$-0.12$-0.14$-0.20$-0.19$-0.24$-0.32$-0.46$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
High Forecast$-0.15$-0.15$-0.16$-0.14$-0.13$-0.10$-0.12$-0.14$-0.17$-0.19$-0.24$-0.32$-0.46$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
Low Forecast$-0.15$-0.15$-0.16$-0.14$-0.13$-0.18$-0.12$-0.14$-0.21$-0.19$-0.24$-0.32$-0.46$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
Surprise %--------0.00%0.00%0.58%0.38%0.02%0.93%1.46%0.91%1.26%1.13%0.80%2.07%1.02%

According to 2 Wall Street analysts, Y-mAbs Therapeutics's projected average Quarter EPS for Jun 21 is $-0.66, with a low estimate of $-0.66 and a high estimate of $-0.66. This represents a -182.92% decrease compared to YMAB previous annual EPS of $0.80 (Mar 21).

Y-mAbs Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
BLUEbluebird bio$0.46$14.132971.74%Hold
PASGPassage Bio$0.60$6.00900.00%Buy
KRONKronos Bio$0.95$7.63703.16%Buy
ZNTLZentalis Pharmaceuticals$3.73$21.86486.06%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
ARQTArcutis Biotherapeutics$8.72$31.00255.50%Buy
STROSutro Biopharma$3.69$11.14201.90%Buy
LRMRLarimar Therapeutics$7.57$20.33168.56%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ERASErasca$2.87$7.00143.90%Buy
CCCCC4 Therapeutics$6.45$13.50109.30%Buy
SNDXSyndax Pharmaceuticals$18.94$36.1190.65%Buy
MRSNMersana Therapeutics$1.84$3.0063.04%Buy
MRUSMerus$51.23$77.1350.56%Buy
YMABY-mAbs Therapeutics$14.87$20.5037.86%Buy
MIRMMirum Pharmaceuticals$40.45$54.5034.73%Buy
EWTXEdgewise Therapeutics$34.48$45.0030.51%Buy
TVTXTravere Therapeutics$18.10$21.3818.12%Buy
PCVXVaxcyte$106.49$124.1416.57%Buy
VECTVectivBio$16.87$18.006.70%Buy
RVMDRevolution Medicines, Inc. Warrant$55.87$58.574.83%Buy

YMAB Forecast FAQ


Yes, according to 6 Wall Street analysts, Y-mAbs Therapeutics (YMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of YMAB's total ratings.

Y-mAbs Therapeutics (YMAB) average price target is $20.5 with a range of $13 to $26, implying a 37.86% from its last price of $14.87. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for YMAB stock, the company can go up by 37.86% (from the last price of $14.87 to the average price target of $20.5), up by 74.85% based on the highest stock price target, and down by -12.58% based on the lowest stock price target.

YMAB's average twelve months analyst stock price target of $20.5 supports the claim that Y-mAbs Therapeutics can reach $20 in the near future.

Y-mAbs Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $93.69M (high $95.61M, low $92.32M), average EBITDA is $-69.094M (high $-61.068M, low $-77.361M), average net income is $-55.378M (high $-45.435M, low $-63.832M), average SG&A $106.09M (high $112.03M, low $100.83M), and average EPS is $-0.546 (high $-0.49, low $-0.569). YMAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $107.41M (high $107.41M, low $107.41M), average EBITDA is $-48.146M (high $-48.146M, low $-48.146M), average net income is $-26.542M (high $-26.542M, low $-26.542M), average SG&A $132.57M (high $132.57M, low $132.57M), and average EPS is $-0.603 (high $-0.603, low $-0.603).

Based on Y-mAbs Therapeutics's last annual report (Dec 2023), the company's revenue was $84.82M, beating the average analysts forecast of $77.83M by 8.98%. Apple's EBITDA was $-25.672M, missing the average prediction of $-61.586M by -58.32%. The company's net income was $-21.427M, missing the average estimation of $-61.467M by -65.14%. Apple's SG&A was $44.86M, missing the average forecast of $96.06M by -53.30%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.945 by -99.95%. In terms of the last quarterly report (Dec 2023), Y-mAbs Therapeutics's revenue was $23.36M, beating the average analysts' forecast of $20.95M by 11.53%. The company's EBITDA was $-74K, missing the average prediction of $-9.39M by -99.21%. Y-mAbs Therapeutics's net income was $-2.281M, missing the average estimation of $-8.628M by -73.56%. The company's SG&A was $11.14M, missing the average forecast of $25.86M by -56.93%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.196 by -99.95%